None listed
Conditions
Brief summary
To compare fibroptic guided intubation through two supraglottic devices. This is helpful in the management of patients with difficult airways where conventional intubation is unable to be achieved
Interventions
Ambu AuraGain LMA 'Registered Trademark'. The Ambu AuraGain will be inserted and after achieving satisfactory ventilation via the supraglottic airway device, fibreopitc-guided tracheal intubation will then commence. A maximum of 2 attempts at intubation will be given. The intubation will be performed by an experienced anaesthetist (>10 years’ since commencement of specialist training) who is familiar with the use of both devices (>10 uses on each device) prior to the study. Assessment of any com
Ambu AuraGain LMA 'Registered Trademark'. The Ambu AuraGain will be inserted and after achieving satisfactory ventilation via the supraglottic airway device, fibreopitc-guided tracheal intubation will then commence. A maximum of 2 attempts at intubation will be given. The intubation will be performed by an experienced anaesthetist (>10 years’ since commencement of specialist training) who is familiar with the use of both devices (>10 uses on each device) prior to the study. Assessment of any complications will occur directly post-operatively in recovery by the anaesthetist performing the intubation.
Sponsors
Elizabeth Judson
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
ASA I, II or III and > 18 years of age, who are scheduled for surgery requiring oro-tracheal intubation at the Royal Melbourne Hospital will be recruited for this study.
Exclusion criteria
Patients who are non-English speaking, require an awake fibreoptic intubation, have a known laryngeal pathology or with contra-indications to the use of supraglottic airway device (weight >100 kg, interincisor distance <2.5cm, or aspiration risk) are not included
Outcome results
None listed